ARVO 2016 Annual Meeting Abstracts 242 Retinal Diseases Monday, May 02, 2016 11:00 AM–12:45 PM Exhibit/Poster Hall Poster Session Program #/Board # Range: 2033–2065/B0238–B0270 Organizing Section: Clinical/Epidemiologic Research Program Number: 2033 Poster Board Number: B0238 Presentation Time: 11:00 AM–12:45 PM Sub-inner limiting membrane macular hemorrhages: diagnosis, etiologies, management and outcome Joël Gambrelle1, Melanie Bressollette-Frappier2, Anne Robinet1. 1 Ophthalmology, Clinique Pasteur Lanroze, Brest, France; 2Novartis France, Rueil Malmaison, France. Purpose: The inner limiting membrane (ILM) is a cell-free membrane on the surface of the retina on which are inserted the fibers of the posterior hyaloïd. Sub-ILM macular hemorrhages (SILMMH) are uncommon and should be differentiated from subhyaloid macular hemorrhages (SHMH) because of their different etiologies. Methods: A retrospective analysis of 11 consecutive cases of SILMMH identified in a french clinical setting was performed: clinical and spectral domain optical coherence tomography (SD -OCT) findings, etiologies, management and outcomes of these cases were described. Results: 11 cases were analyzed: 8 were females and mean age was 55 years [24y - 83y]. All patients have been referred with sudden visual impairment (Best corrected visual acuity (BCVA) was limited to 20/2000 or less in 9 cases) and premacular hemorrhage. All patients underwent a SD-OCT which confirm the diagnosis of SILMMH. SILMMH was isolated (3 cases) or combined with vitreous hemorrhages (1 case), with SHMH (1 case), with intraretinal hemorrhages (7 cases) or with sub-retinal hemorrhage (1 case). In 5 cases, posterior vitreous detachment was present at diagnosis. Etiologies of SILMMH were a rupture of a retinal macro-aneurysm (4 cases), a Vasalva maneuver (2 cases), a Terson’s syndrome (2 cases), a severe anemia (1 case), a retinal vein occlusion (1 case) and a laser injury (1 case). In 6 cases the management of SILMMH consisted in simple monitoring. In one of them, spontaneous resorption of the SILMMH revealed a full thickness macular hole. The SILMMH related to retinal vein occlusion has been treated by ranibizumab intravitreal injections due to its combination with a macular edema. The 4 SILMMH related to the rupture of a retinal macro-aneurysm have been treated by early pars plana vitrectomy combined with ILM peeling, hemorrhage aspiration and endolaser photocoagulation of the macro-aneurysm. Procedure-related retinal detachment occured in one case. After 6 months of follow-up and complete resorption of hemorrhage, BCVA was superior to 20/40 for 9/11 patients. Conclusions: Despite an almost identical clinical presentation SILMMH and SHMH have usually distinct pathophysiological origins: unlike the SHMH is usually due to bleeding from a preretinal neovessel consecutive to retinal ischemia, causes of SILMMH seems rather bleeding from retinal vessels themselves. Most of the SILMMH showed good anatomic and functional outcomes. Commercial Relationships: Joël Gambrelle, None; Melanie Bressollette-Frappier, Novartis; Anne Robinet, None

Program Number: 2034 Poster Board Number: B0239 Presentation Time: 11:00 AM–12:45 PM Spontaneous Intrapapillary Haemorrhage and Adjacent Peripapillary Subretinal Haemorrhage in Adolescents Caryssa L. Yan1, Marten E. Brelen2, Haoyu Chen3, Chi Pui C. Pang2, 3, Weiqi Chen3. 1Chinese University of Hong Kong, New Territories, Hong Kong; 2Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Kowloon, Hong Kong; 3Joint Shantou International Eye Centre, Shantou, China. Purpose: To report the clinical features of 7 eyes of 7 adolescent patients with spontaneous intrapapillary haemorrhage with adjacent peripapillary subretinal haemorrhage (IHAPSH). Methods: A retrospective case series of 7 patients who were all seen at the Joint Shantou International Eye Centre, between 2006 and 2014, was performed. The patient demographics, clinical history, vision, fundoscopic appearance and results of relevant investigations were collected. Results: 7 eyes of 7 patients (4 male and 3 female) with IHAPSH with a median age at presentation of 15 years (mean 14.7, range 11-19). 4 cases presented in the right eye and 3 cases in the left eye. The presenting visual acuity ranged from 0.12 - 1.00. There were no obvious underlying causes or predisposing factors. 6 eyes had myopia ranging mild to moderate (–0.25 diopters (D) to –4.00D) and none had tilted discs. In 4 eyes, the subretinal haemorrhage was greater than 2 disc diameters. There was associated vitreous haemorrhage in 5 eyes. There were no posterior vitreous detachments in any of the eyes. Optic disc drusen was found in 1 eye. Visual field test showed an enlarged blind spot in 4 cases. Optical coherence tomography of the disc revealed optic disc swelling in 2 cases. Fluorescein angiography demonstrated leakage in the late phase of 3 eyes. At 2 to 24 months follow-up, the haemorrhage resolved in all 7 cases with vision recovering fully to 20/20. Visual field defect of enlarged blind spots improved with the resolution of intrapapillary and subretinal hemorrhages. Conclusions: The condition of IHAPSH resolved spontaneously without intervention in all cases. There appeared to be no predisposing factors for the development of this condition. Previously reported risk factors such as straining (Valsalva), posterior vitreous detachment or unusual configuration of the disc were not seen in these cases. This is the first time a series of young adults have been reported with this condition all of whom presented in the same manner and had the same clinical outcomes. Commercial Relationships: Caryssa L. Yan, None; Marten E. Brelen; Haoyu Chen, None; Chi Pui C. Pang, None; Weiqi Chen, None Program Number: 2035 Poster Board Number: B0240 Presentation Time: 11:00 AM–12:45 PM Case Report of Acute Posterior Multifocal Placoid Pigment Epitheliopathy in a 13 Year Old Male Laura Kueny1, David Spinak2. 1Georgetown University, Herndon, VA; 2 Retina Center Northwest, Silverdale, WA. Purpose: To report a case of Acute Posterior Multifocal Placoid Pigment Epitheliopathy in a young healthy male patient with Native American ancestry. Methods: Case report describing the presentation and findings of Acute Posterior Multifocal Pigment Epitheliopathy in this patient. Information regarding this patient was collected from Retina Center Northwest in Silverdale Washington. Results: The patient is a 13 year old male that noticed sudden onset of central blurry vision in his right eye that started two weeks prior

These abstracts are licensed under a Creative Commons Attribution-NonCommercial-No Derivatives 4.0 International License. Go to http://iovs.arvojournals.org/ to access the versions of record.

ARVO 2016 Annual Meeting Abstracts to presentation. On the initial visit his visual acuity was 20/25 in the right eye, 20/20 in the left eye and his dilated exam and Optical coherence tomography (OCT) showed findings consistent with subretinal fluid of the right eye. Fluorescein Angiography of the right eye demonstrated early blockage and late leakage in the macula, in addition to late staining of the macula and optic nerve head. Indocyanine Green Angiography in the right eye demonstrated significant blockage in the macula consistent with inflamed retinal pigment epithelium (RPE). In the left eye ICG also demonstrated early blockage in the macula consistent with inflamed RPE. Subsequent infectious and autoimmune work up performed on the patient at that time was negative. Conclusions: This case represents a unique presentation of Acute Posterior Multifocal Placoid Pigment Epitheliopathy in a young patient of Native American ancestry. There is significant macular edema and blockage of blood flow of the macula in both eyes that is not consistent with the minimal decrease in his visual acuity in the right eye, and no change in vision in his left eye. In conclusion, this slight change in visual acuity could have easily gone undetected by the patient or nonspecialized clinician. It is known that Acute Posterior Multifocal Pigment Epitheliopathy is associated with cerebral vasculitis, therefore missing this diagnosis in younger populations presenting with minimal visual symptoms could be detrimental. Commercial Relationships: Laura Kueny, None; David Spinak, None Program Number: 2036 Poster Board Number: B0241 Presentation Time: 11:00 AM–12:45 PM Exogenous Testosterone Use and Central Serous Chorioretinopathy Yicheng Chen, Bradley T. Smith. The Retina Institute, St. Louis, MO. Purpose: Central serous chorioretinopathy (CSCR) has been associated with psychosocial stress, systemic corticosteroid use, type A personality, pregnancy and endogenous Cushing’s syndrome. Case reports in the literature suggest a possible link between CSCR and testosterone. We performed a retrospective chart review of patients with CSCR between 2013 and 2015 to examine the prevalence of testosterone use among CSCR patients and the clinical characteristics of CSCR in the setting of exogenous testosterone use. Methods: Patients seen between 2012 and 2015 who have a diagnosis of CSCR were identified through the electronic medical record of a large retina practice. The electronic records of all patients with a history of exogenous testosterone use and a diagnosis of CSCR were reviewed. Results: 480 patients with a diagnosis of CSCR were identified, of which 7 patients had a history of exogenous testosterone use (1.46%). 0/7 patients reported any other steroid use. The age of the patients ranged from 36-55 (mean 46.57) and all were male. Only the right eye was involved in all 7 patients. Testosterone was discontinued in only 1/7 patients. 6/7 patients had a visual acuity of 20/40 or better at last follow-up (range 20/20 to 4/200). 4/7 (57%) had resolution of subretinal fluid at their last visit. Conclusions: CSCR patients with a history of exogenous testosterone use accounted for a small percentage of all CSCR patients in the study (1.46%). The majority of patients in this study recovered 20/40 or better vision and 57% had resolution of subretinal fluid on OCT, suggesting a generally favorable prognosis for CSCR in the setting of testosterone supplementation, even without discontinuation of testosterone. Future studies on a larger scale are needed to elucidate the role, if any, that testosterone plays in central serous chorioretinopathy.

Table 1. Patient Clinical Characteristics. *Patient 2 developed subsequent CNVM in the right eye. Commercial Relationships: Yicheng Chen, None; Bradley T. Smith Program Number: 2037 Poster Board Number: B0242 Presentation Time: 11:00 AM–12:45 PM INTRAVITREAL BEVACIZUMAB PLUS BRINZOLAMIDE VERSUS INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY: PILOT STUDY Jesús Ramón Alvarez-Félix, PIMENTEL KARLA, SILVIA PAZ, YOLANDA CHAVEZ ROMERO, ABEL RAMON, David Magana, Sergio Sital-Gastelum, Efrain Romo-Garcia. CIDOCS, Universidad Autonoma de Sinaloa, Culiacan, Mexico. Purpose: Controversy exists regarding to achieve a faster and better outcome after a central serous chorioretinopathy (CSC). We perform a pilot study to compare the efficacy of intravitreal bevacizumab plus brinzolamide versus intravitreal bevacizumab for CSC. Methods: Patients diagnosed with CSC were recruited from July to October 2015, of any age and sex, without prior treatment or other ocular pathology. They were divided randomly into 3 groups: group 1 = intravitreal bevacizumab, group 2 = topical brinzolamide bid for 2 weeks followed by intravitreal bevacizumab, group 3 = brinzolamide bid for 4 weeks; we analyze the following variables: sex, age, initial BCVA and the primary outcomes variables: final best corrected visual acuity (BCVA, expressed in LogMAR) and central foveal thickness (CFT, in µm) measured by SD-OCT at baseline and at 4 weeks. Results: We analyze 35 patients using ANOVA for 3 treatment groups, we found 77.1% were male and 51.4% had involvement of the right eye. Group 1 n=12 patients, group 2 n=12 patients, group 3 n=11. The age range was from 22 to 65 years, with an average age of 38+11.3. An initial average of uncorrected visual acuity (LogMAR) of 0.329 in group 1, 0.409 in group 2, 0.410 in group 3 (p = 0.794). We found a statistically significant difference in group 1 (Bevacizumab) between the initial and final BCVA (LogMAR) with an improvement in the average of -0.100 (p = 0.002), the final CFT average obtained were: group 1= 286.7±57.4, group 2= 296.1±61.9, group 3= 283.3±30.8; this results were similar in 3 groups and statistically different from initial CFT (p=0.000, p=0.000 and p=0.008 respectively). Conclusions: We found statistically significant difference in the final BCVA in the bevacizumab group, towards a better final BCVA in group 1, however 3 groups had good final BCVA and CFT. Commercial Relationships: Jesús Ramón AlvarezFélix; PIMENTEL KARLA, None; SILVIA PAZ, None; YOLANDA CHAVEZ ROMERO, None; ABEL RAMON, None; David Magana, None; Sergio Sital-Gastelum, None; Efrain Romo -Garcia, None

These abstracts are licensed under a Creative Commons Attribution-NonCommercial-No Derivatives 4.0 International License. Go to http://iovs.arvojournals.org/ to access the versions of record.

ARVO 2016 Annual Meeting Abstracts Program Number: 2038 Poster Board Number: B0243 Presentation Time: 11:00 AM–12:45 PM Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: 48 Month Results from the Phase 1 Safety Trial Traci E. Clemons1, Emily Y. Chew2, Tunde Peto3, Ferenc B. Sallo3, Irene Leung3. 1Ophthalmology, Emmes Corporation, Rockville, MD; 2National Eye Institute/NIH, Bethesda, MD; 3NIHR BMRC at Moorfields Eye Hospital and UCL, London, United Kingdom. Purpose: To assess functional and structural progression after 48 months of treatment with ciliary neurotrophic factor (CNTF) delivered using an encapsulated cell implant for the treatment of macular telangiectasia (MacTel) Type 2. Methods: MacTel Type 2 affects both eyes and is characterized by retinal opacification, vascular telangiectasis, right-angle venules, intra-retinal crystalline deposits, foveal thinning, retinal pigment epithelial hypertrophy, and, in some cases, intra-/subretinal neovascularization. This neurodegenerative disease is considered to result from the loss of Mueller cells, resulting in loss of photoreceptors. A Phase 1 open label, non-randomized Phase 1 study was conducted to assess ocular safety after implantation of the CNTF-secreting capsule. Secondary efficacy outcomes included change in visual acuity, optical coherence tomography en face measurements of the disruption in the ellipsoid zone, and microperimetry comparisons between baseline and 48 months of treatment. Results: A total of seven participants were enrolled in the study. The mean ± standard deviation (SD) change in best corrected visual acuity (BCVA, 48 months - baseline) was 1.17 ± 0.48 (p=0.06) letters in CNTF implanted (study) eyes versus -5.50 ± 1.88 (p=0.03) letters in fellow eyes. The difference between study/fellow eyes met statistical significance (6.67 ± 1.52; 95% CI: 2.32 – 9.13; p=0.007). All study eyes experienced an increase of 10dB in at least one point as measured by microperimetry compared with 1 of 5 fellow eyes (p=0.05). The mean change in ellipsoid zone viewed “en face” at 48 months was 0.27 ± 0.13 mm2 (p=0.10) in the study eyes and 0.60 ± 0.30 mm2 (p=0.11) in the fellow eyes. The difference between study/fellow eye did not meet statistical significance (mean difference=-0.33 ± 0.25; 95% CI: 0.34 – 1.62; p=0.26). Conclusions: These data provide preliminary data on potential efficacy parameters to assess the CNTF implant as a treatment for MacTel Type 2 in future studies. Commercial Relationships: Traci E. Clemons, None; Emily Y. Chew, None; Tunde Peto, None; Ferenc B. Sallo, None; Irene Leung Support: Funding provided by The Lowy Medical Research Institute Limited Clinical Trial: NCT01327911 Program Number: 2039 Poster Board Number: B0244 Presentation Time: 11:00 AM–12:45 PM Assessment of the implementation of the revised recommendations for screening of hydroxychloroquine retinopathy in the clinical practice of opthalmologists and rheumatologists Shiri Shulman1, 2, Wolman Jonathan3, 2, Dafna Paran3, 2. 1 ophthalmology, tel-aviv medical center, Tel Aviv, Israel; 2Tel-Aviv University, Tel aviv, Israel; 3Rheumatology, tel-aviv medical center, Tel aviv, Israel. Purpose: The AAO published in 2011 revised recommendations regarding screening for hydroxychloroquine(HCQ) toxicity. The aim of this study was to assess the implementation of these recommendations by rheumatologists and ophthalmologists.

Methods: A questionnaire pertaining to each physician’s routine practice in the follow up of patients treated with HCQ was distributed among all members of the Israeli societies of Rheumatology and Ophthalmology as a web survey. The results collected and analysed using SPSS statistical softwere. Results: 121 physicians responded to the questionnaire, 49 rheumatologists and 71 ophthalmologists. 82.6% recommended a baseline ophthlamologic examination for all patients while 7.4% recommend baseline evaluation only for patients at risk. 42% of all responders unnecesserily postponed initiation of HCQ treatment until completion of a baseline evaluation. Only 0.6% of the rheumatologists and 19% of the ophthalomologists were aware of the recommended assessments. 30% of the responders recommended red-on-white VF, 14% recommended 24-2 VF, while a similar percentage recommended these tests for follow up (33%,13% respectively). When one abnormal test was detected 56% recommended cessation of therapy while 23% recommended additional evaluation. 86 % recommended a yearly or even more frequent follow-up. 83% of the responders were not aware of all of the known risk factors for HCQ toxicity The differences between ophthalmologists and rheumatologists were not statistically signifficant (P>0.05) Conclusions: Physicians are unaware of the recommendations regarding screening for HCQ retinal toxicity. Use of inappropriate tests may lead to unnecessary cessation of HCQ treatment while lack of consideration of risk factors may pose patients at risk for toxicity. Commercial Relationships: Shiri Shulman, None; Wolman Jonathan; Dafna Paran, None Program Number: 2040 Poster Board Number: B0245 Presentation Time: 11:00 AM–12:45 PM Association of retinal nerve fiber layer thickness and systemic hypertension Robert J. White1, James Kohler1, Dara D. Koozekanani2, Afshin Divani3. 1University of Minnesota Medical School, Minneapolis, MN; 2Department of Ophthalmology, University of Minnesota, Minneapolis, MN; 3Department of Neurology, University of Minnesota, Minneapolis, MN. Purpose: Structural losses in the retina nerve fiber layer (RNFL) are known to result from glaucoma, and have also been associated with cerebrovascular disease. For this study, we investigated the relationship between systemic hypertension and RNFL thickness. Methods: After informed consent was obtained, clinic patients were recruited into both hypertensive and non-hypertensive groups, based on known prior diagnosis by their primary care physician. Patients were excluded if they had diabetes, retinal vascular occlusion, or other retinal disorders which could affect retinal vessel diameter. Patients were also excluded if they had known prior glaucoma, ocular hypertension, or cerebrovascular disease. Patients had a baseline interview, during which their medical history was obtained and their blood pressure was measured using automated arm plethysmography (Welch Allyn). For each eye, the RNFL was assessed using optical coherence tomography (OCT) (Spectralis, Heidelberg Engineering) using a standard circle scan. Results: A total of 64 patients and 126 eyes were analyzed (hypertension 32 patients, 63 eyes; non-hypertension 32 patients, 63 eyes). There were no significant differences in the age, gender or racial composition of the groups. All but one of the patients in the hypertension (HTn) group regularly took antihypertensive medications. Six patients in the non-hypertension (non-HTn) group regularly took an antihypertensive medication or a medication with major antihypertensive properties for other reasons. The average systolic blood pressure as assessed by automated plethysmography

These abstracts are licensed under a Creative Commons Attribution-NonCommercial-No Derivatives 4.0 International License. Go to http://iovs.arvojournals.org/ to access the versions of record.

ARVO 2016 Annual Meeting Abstracts was significantly higher in the HTn group (139.0 mmHg) than in the non-HTn group (134.5 mmHg); p=0.03. There was no significant difference in diastolic blood pressure. The RNFL was thinner, both globally and for all sectors in the HTn group, but only the inferonasal sector rose to statistical significance. Conclusions: Systemic hypertension was associated with decreased thickness of the RNFL, though this was only significant in the inferonasal sector for this study.

Table 1: RNFL thickness assessed by optical coherence tomography in non-glaucomatous eyes of patients with and without systemic hypertension. NS - supranasal; N - nasal; NI - infranasal; TI infratemporal; T - temporal; TS - supratemporal; G - global. Commercial Relationships: Robert J. White, None; James Kohler, None; Dara D. Koozekanani, None; Afshin Divani, None Program Number: 2041 Poster Board Number: B0246 Presentation Time: 11:00 AM–12:45 PM The MacTel Project – Enrolling a Phase 2 Clinical Trial Jennifer K. Trombley. Lowy Medical Research Institute, La Jolla, CA. Purpose: Enrolling a clinical trial in a timely manner may be the greatest obstacle when conducting clinical research. The MacTel Project’s Natural History Observation and Registry Study (NHOR) enrolls persons with Macular Telangiectasia Type 2. One of the Registry’s primary objectives is to maintain contact with potential participants for clinical trials. Despite having a more than adequate number of pre-identified potential participants at selected Registry sites, a Phase 2 clinical trial took over a year to enroll and necessitated adding additional sites. A retrospective, descriptive study was undertaken to determine why participants declined to screen. Also, to determine the amount of work/time required to identify a sufficient number of participants to meet enrollment goals. Methods: Nine NHOR study sites were selected to participate in the trial based on the numbers of potentially eligible participants. Two additional sites were later added to achieve enrollment goals. All 11 sites were asked to complete a questionnaire based on their best recollection of the enrollment process. The questionnaire listed possible reasons given by potentially eligible persons for not wanting to participate. The sites reported the number of persons citing each reason. The sites could add other reasons not represented in the questionnaire. The sites were also asked to recall the number of medical/study records they reviewed to identify individuals that were eligible to screen, how many were contacted and how many actually screened. Results: Nine of eleven sites responded to the survey (81%). The responding sites reported that 311 patient records were reviewed in order to identify 198 persons to contact. Of those, 91 agreed to screen. Assuming a minimum of 15 minutes per record review and time attempting contact, the sites spent over 40 uncompensated hours in prescreening activities. The most common reason given for not participating was vision was stable and treatment was too risky; the same themes were seen across all sites. Conclusions: Interest in participating in a clinical trial may be influenced by the type of trial (surgical intervention more risky than a medication trial) and perceived severity of the affected persons’

condition. Documentation of recruiting activities may be used to increase compensation from the sponsor. These results may be used to more accurately project the time and work involved in enrolling future similar studies. Commercial Relationships: Jennifer K. Trombley, Lowy Medical Research Institute (C) Support: Lowy Medical Research Institute Clinical Trial: NCT01949324 Program Number: 2042 Poster Board Number: B0247 Presentation Time: 11:00 AM–12:45 PM Familial Exudative Retinopathy: A Case Series Alexander L. Pleet, Andrew W. Francis, Felix Y. Chau. Ophthalmology, University of Illinois Eye and Ear Infirmary, Chicago, IL. Purpose: Familial exudative vitreoretinopathy (FEVR) is an uncommon eye disorder affecting the growth and development of retinal vasculature. It can lead to visual impairment and sometimes complete blindness if left untreated. Given its rarity, knowledge of FEVR is limited to a handful of retrospective single center studies. The purpose of this retrospective, non-randomized case series is to describe the clinical characteristics, staging, and medical/surgical management of patients with FEVR at the University of Illinois at Chicago (UIC) in order to add to the collective data on FEVR and better understand the manifestations and natural history of this visionthreatening disorder. Methods: Through a search of the electronic clinical database at UIC, study patients between age 0 to 65 years with a clinical diagnosis of FEVR were identified and included. Exclusion criteria included any other significant retinal disease or absence of fundus photography for clinical staging. For all included patients, clinical information was recorded including age at diagnosis, gender, eyes affected, family history, genetics where possible, FEVR stage, and treatment. Staging was accomplished by examination of fundus photography or RetCam images by a single retina specialist. Results: A total of 23 patients met the inclusion criteria for FEVR (4 adults, 19 children). Twelve patients were male and 11 were female. The mean age of adults was 38 years ± 7 and for children was 3 years ± 4. A family history of FEVR was identified in 11 patients (48%). A review of fundus photographs revealed the median stage of FEVR for all patients was 2.5 OD and 2.0 OS. Genetic testing identified two patients with a Norrie gene mutation and both underwent complex surgical repair. Regarding management, 8 patients (35%) required observation only (16 eyes, mean stage 1.4). A total of 15 patients required surgical or laser intervention. Peripheral laser ablation was the sole procedure applied to 3 patients (5 eyes, mean stage 3). Pars plana vitrectomy or scleral buckle placement were necessary for the remaining 12 patients (17 eyes, mean stage 4). Conclusions: In this retrospective review of all FEVR cases at UIC, FEVR presents in variable stages and is managed according to disease severity, from simple observation in mild forms to laser and invasive surgery for progressively more severe forms. Genetic testing may reveal known or new mutations in associated genes to help confirm the diagnosis of FEVR. Commercial Relationships: Alexander L. Pleet, None; Andrew W. Francis, None; Felix Y. Chau, None Support: Research to Prevent Blindness Department Grant, UIC Core Grant NEI EY01792, NEI K12 EY021475

These abstracts are licensed under a Creative Commons Attribution-NonCommercial-No Derivatives 4.0 International License. Go to http://iovs.arvojournals.org/ to access the versions of record.

ARVO 2016 Annual Meeting Abstracts Program Number: 2043 Poster Board Number: B0248 Presentation Time: 11:00 AM–12:45 PM SYSTEMIC ASSOCIATIONS IN CENTRAL SEROUS RETINOPATHY The MultiCenter Controlled Personality Analysis In CSR Mona Koaik1, Ahmad M. Mansour1, Luiz H. Lima2, Maha Shahin3, Sami H. Uwaydat4. 1Ophthalmology, AUBMC, Beirut, Lebanon; 2 Federal University of Sao Paolo, Sao Paolo, Brazil; 3Ophthalmology, Mansoura University, Mansoura, Egypt; 4University of Arkansas, Little Rock, AR. Purpose: Central serous retinopathy (CSR) is characterized by macular detachment due to hyperpermeable retinal pigment epithelium and choroid mostly affecting young men under perceived stress. While most previous studies have been retrospective and have focused on a single facet of the patient’s personality, we conducted a prospective multicenter/multinational controlled study to dissect the multifaceted personality profile in CSR. Methods: The authors themselves interviewed CSR patients and control patients without retinal disease from November 2014 to October 2015 using a long questionnaire in clinic setting. Controls were matched for age, gender and race across 3 continents. Statistical analyses were done using bivariate analysis (Chi-square at the 95% confidence interval) on SPSS Software (v. 22). Results: 64 consecutive CSR patients (mean age 46; male 78.1%) and 66 controls (mean age 44.9; male 78.8%) were analyzed for 59 variables. The results were divided into 3 categories according to strength of the association. Very strong associations included type A personality (p